上海医药：马来酸阿伐曲泊帕片获得批准生产

Core Viewpoint - Shanghai Pharmaceuticals (601607) has received regulatory approvals for two of its products, indicating a positive development in its product pipeline and potential for revenue growth [1]. Group 1: Product Approvals - The company's subsidiary, Shanghai Pharmaceuticals Holding Co., Ltd., has obtained a Drug Registration Certificate from the National Medical Products Administration for its drug, Avatrombopag Maleate Tablets, allowing it to commence production [1]. - Additionally, the company's Changzhou Pharmaceutical Factory has received a Drug Registration Certificate from the Health Sciences Authority of Singapore for its drug, Prucalopride Capsules, enabling it to be marketed [1].